. 2021 Sep 8;10:100222. doi: 10.1016/j.lanepe.2021.100222

Table 1.

Likelihood of non-adherence to antithrombotic therapy at 6 months and 12 months in patients with liver disease. Adjusted odds ratios (ORs) are reported.

	Anticoagulants (6 months)				Anticoagulants (12 months)					Antiplatelets (6 months)				Antiplatelets (12 months)
	OR	Lower CI	Upper CI	P value	OR	Lower CI	Upper CI	P value		OR	Lower CI	Upper CI	P value	OR	Lower CI	Upper CI	P value
Female	0.61	0.44	0.83	0.0018	0.64	0.46	0.91	0.011	Female	0.79	0.66	0.95	0.014	0.84	0.69	1.02	0.072
Age									Age
Age 30 - 49	1.00 (ref)				1.00 (ref)				Age 30 - 49	1.00 (ref)				1.00 (ref)
Age 50 - 59	2.71	1.05	7.06	0.038	1.28	0.41	3.67	0.66	Age 50 - 59	0.92	0.65	1.30	0.64	0.74	0.51	1.07	0.11
Age 60 - 69	1.62	0.68	3.82	0.27	0.85	0.29	2.20	0.76	Age 60 - 69	0.88	0.63	1.24	0.48	0.77	0.54	1.09	0.15
Age 70 - 79	1.42	0.61	3.31	0.41	0.80	0.28	2.03	0.65	Age 70 - 79	0.90	0.64	1.28	0.57	0.78	0.54	1.11	0.17
Age 80 & above	0.93	0.39	2.23	0.87	0.42	0.14	1.09	0.09	Age 80 & above	0.48	0.32	0.71	0.00033	0.49	0.32	0.75	0.0011
Comorbidities									Comorbidities
Chronic kidney disease	0.77	0.55	1.09	0.14	0.65	0.45	0.95	0.025	Chronic kidney disease	0.72	0.56	0.91	0.0054	0.77	0.60	0.98	0.037
Ascites	1.16	0.75	1.82	0.51	1.12	0.69	1.84	0.66	Ascites	1.03	0.81	1.32	0.79	1.14	0.88	1.48	0.34
Cirrhosis	1.25	0.92	1.71	0.15	1.23	0.88	1.73	0.23	Cirrhosis	1.17	0.98	1.40	0.086	1.24	1.02	1.50	0.027
Hepatic encephalopathy	0.90	0.47	1.75	0.75	1.09	0.53	2.35	0.83	Hepatic encephalopathy	0.80	0.57	1.13	0.20	0.96	0.67	1.39	0.84
Varices	1.49	0.86	2.64	0.16	1.70	0.94	3.29	0.093	Varices	1.25	0.94	1.66	0.12	1.34	1.00	1.82	0.056
Proton pump inhibitor use	0.82	0.60	1.12	0.21	0.99	0.71	1.38	0.94	Proton pump inhibitor use	0.73	0.61	0.88	0.0010	0.79	0.65	0.96	0.017
CHA₂DS₂ VASc score									CHA₂DS₂ VASc score
0-1	1.00 (ref)				1.00 (ref)				0-1	NA				NA
2	0.70	0.39	1.23	0.22	0.63	0.33	1.19	0.16	2	NA				NA
3-4	0.69	0.43	1.12	0.14	0.53	0.30	0.91	0.024	3-4	NA				NA
5-9	0.51	0.30	0.83	0.0080	0.44	0.24	0.77	0.0052	5-9	NA				NA
Child-Pugh score									Child-Pugh score
Class A (score 5-6)	1.00 (ref)				1.00 (ref)				Class A (score 5-6)	1.00 (ref)				1.00 (ref)
Class B (score 7-9)	1.23	0.89	1.69	0.21	1.10	0.78	1.55	0.60	Class B (score 7-9)	1.10	0.91	1.34	0.32	1.11	0.91	1.36	0.30
Class C (score 10-15)	0.75	0.14	4.11	0.73	1.19	0.86	2.85	0.97	Class C (score 10-15)	1.36	0.64	3.01	0.43	1.15	0.52	2.63	0.74
FIB-4 score									FIB-4 score
< 1.45	1.00 (ref)				1.00 (ref)				< 1.45	1.00 (ref)				1.00 (ref)
1.45-3.25	0.83	0.60	1.14	0.25	0.87	0.61	1.23	0.43	1.45-3.25	0.84	0.69	1.01	0.066	0.88	0.72	1.07	0.20
>3.25	0.59	0.33	1.04	0.066	0.68	0.37	1.26	0.21	>3.25	1.18	0.83	1.69	0.35	1.48	1.00	2.22	0.056
Warfarin time in therapeutic range (TTR)
TTR > 60%	0.73	0.46	1.15	0.18	0.52	0.31	0.87	0.013
Medication type									Medication type
Warfarin	1.00 (ref)				1.00 (ref)				Aspirin	1.00 (ref)				1.00 (ref)
Apixaban	0.52	0.34	0.78	0.0015	0.51	0.33	0.80	0.0029	Clopidogrel	0.72	0.61	0.85	0.00011	0.79	0.67	0.94	0.0092
Rivaroxaban	0.44	0.29	0.67	< 0.0001	0.36	0.23	0.56	< 0.0001	Dipyridamole	0.92	0.63	1.37	0.68	1.27	0.83	1.98	0.27